Compare LQDA & PTON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | PTON |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Recreational Games/Products/Toys |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2020 | 2019 |
| Metric | LQDA | PTON |
|---|---|---|
| Price | $37.80 | $5.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $41.00 | $8.05 |
| AVG Volume (30 Days) | 1.1M | ★ 14.9M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 51.81 | ★ 80.13 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $158,320,000.00 | N/A |
| Revenue This Year | $278.87 | N/A |
| Revenue Next Year | $57.13 | $0.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1031.18 | N/A |
| 52 Week Low | $11.85 | $3.65 |
| 52 Week High | $46.67 | $9.20 |
| Indicator | LQDA | PTON |
|---|---|---|
| Relative Strength Index (RSI) | 49.78 | 67.87 |
| Support Level | $31.75 | $4.44 |
| Resistance Level | $39.19 | $6.97 |
| Average True Range (ATR) | 2.12 | 0.28 |
| MACD | 0.09 | 0.08 |
| Stochastic Oscillator | 37.52 | 91.55 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product derives revenue from the portfolio of Connected Fitness Products and related accessories, as well as Precor-branded fitness products, delivery and installation services, Peloton Bike portfolio rental products, extended warranty agreements, branded apparel, and commercial service contracts. Subscription revenue is derived from monthly Subscription fees. The company generates maximum revenue from the Subscription segment. Geographically, the company derives a majority of its revenue from North America and the rest from International markets.